Suppr超能文献

系统性硬化症患者、原发性雷诺现象患者及正常对照者的血清基质金属蛋白酶组织抑制因子-1、基质金属蛋白酶组织抑制因子-2和基质金属蛋白酶-1 。

Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

作者信息

Young-Min S A, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston T E

机构信息

Department of Rheumatology, University of Newcastle-upon-Tyne, UK.

出版信息

Ann Rheum Dis. 2001 Sep;60(9):846-51.

Abstract

BACKGROUND

Excess tissue matrix accumulates in systemic sclerosis (SSc), accounting for both visceral and dermal fibrosis. It is suggested that decreased serum levels of matrix metalloproteinases (MMPs) or increased levels of tissue inhibitors of matrix metalloproteinases (TIMPs) may account for this matrix accumulation.

OBJECTIVE

To measure serum levels of tissue inhibitors of metalloproteinases, TIMP-1, TIMP-2, and collagenase-1 (MMP-1), in patients with diffuse cutaneous systemic sclerosis (dcSSc), limited cutaneous systemic sclerosis (lcSSc), primary Raynaud's phenomenon (RP), and in normal controls.

METHODS

Serum samples from patients with dcSSc (n=83), lcSSc (n=87), RP (n=80), and normal controls (n=98) were analysed using enzyme linked immunosorbent assays (ELISAs) for total TIMP-1, TIMP-2, and MMP-1. Results from each assay were analysed by the Kruskal-Wallis test. Dunn's multiple comparison post-test was then applied between groups.

RESULTS

TIMP-1 levels were significantly raised in dcSSc and lcSSc groups compared with the RP group and normal controls (p<0.01 to p<0.001). In the dcSSc group, TIMP-1 levels were significantly higher in early disease (<2 years) than in late stage disease (>4 years) (p<0.05). This was not found for the lcSSc group. Serum TIMP-2 and MMP-1 levels in dcSSc and lcSSc did not differ significantly from those in normal controls. Increased levels of TIMPs were not convincingly associated with organ disease. No assay result correlated with autoantibody status (anti-topoisomerase 1 (anti-Scl-70), anticentromere antibody, or anti-RNA polymerase). No significant differences in serum TIMP-1, TIMP-2, or MMP-1 levels were shown in the RP group compared with normal controls.

CONCLUSIONS

Raised TIMP-1 levels in the SSc groups support the hypothesis that matrix accumulation occurs in SSc at least in part owing to decreased degradation. Moreover, the variation in TIMP-1 levels between the early and late disease stages of dcSSc seems to reflect the early progressive course of dermal fibrosis seen clinically. The expected reduction in serum MMP-1 levels in the SSc groups was not found. This suggests that tissue matrix accumulation is due to increased inhibitors rather than to decreased MMPs.

摘要

背景

过量的组织基质在系统性硬化症(SSc)中积聚,导致内脏和皮肤纤维化。有研究表明,血清中基质金属蛋白酶(MMPs)水平降低或基质金属蛋白酶组织抑制剂(TIMPs)水平升高可能是造成这种基质积聚的原因。

目的

测量弥漫性皮肤系统性硬化症(dcSSc)、局限性皮肤系统性硬化症(lcSSc)、原发性雷诺现象(RP)患者及正常对照者血清中金属蛋白酶组织抑制剂TIMP-1、TIMP-2和胶原酶-1(MMP-1)的水平。

方法

采用酶联免疫吸附测定(ELISA)法分析dcSSc患者(n = 83)、lcSSc患者(n = 87)、RP患者(n = 80)及正常对照者(n = 98)的血清样本,检测总TIMP-1、TIMP-2和MMP-1水平。各检测结果采用Kruskal-Wallis检验进行分析,然后在组间应用Dunn多重比较后检验。

结果

与RP组和正常对照组相比,dcSSc组和lcSSc组的TIMP-1水平显著升高(p<0.01至p<0.001)。在dcSSc组中,疾病早期(<2年)的TIMP-1水平显著高于疾病晚期(>4年)(p<0.05)。lcSSc组未发现此现象。dcSSc组和lcSSc组的血清TIMP-2和MMP-1水平与正常对照组相比无显著差异。TIMP水平升高与器官疾病之间无令人信服的关联。没有检测结果与自身抗体状态(抗拓扑异构酶1(抗Scl-70)、抗着丝点抗体或抗RNA聚合酶)相关。与正常对照组相比,RP组的血清TIMP-1、TIMP-2或MMP-1水平无显著差异。

结论

SSc组中TIMP-1水平升高支持以下假说,即SSc中基质积聚至少部分是由于降解减少所致。此外,dcSSc疾病早期和晚期TIMP-1水平的变化似乎反映了临床上所见的皮肤纤维化的早期进展过程。未发现SSc组血清MMP-1水平如预期那样降低。这表明组织基质积聚是由于抑制剂增加而非MMPs减少所致。

相似文献

2
Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Eur J Neurol. 2010 Feb;17(2):226-31. doi: 10.1111/j.1468-1331.2009.02775.x. Epub 2009 Oct 1.
4
Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.
J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):70-5. doi: 10.1016/s0190-9622(00)90011-2.
6
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Plast Reconstr Surg. 2003 Oct;112(5):1279-86. doi: 10.1097/01.PRS.0000081462.40448.49.
7
Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.
Biomed Res Int. 2020 Apr 21;2020:6416514. doi: 10.1155/2020/6416514. eCollection 2020.
8
Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis.
Clin Exp Dermatol. 2002 Jun;27(4):301-5. doi: 10.1046/j.1365-2230.2002.01011.x.

引用本文的文献

1
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Stem Cell Res Ther. 2024 Jun 18;15(1):170. doi: 10.1186/s13287-024-03782-5.
2
Back to the future: targeting the extracellular matrix to treat systemic sclerosis.
Nat Rev Rheumatol. 2023 Nov;19(11):713-723. doi: 10.1038/s41584-023-01032-1. Epub 2023 Oct 3.
4
Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients.
Cells. 2023 Jan 19;12(3):368. doi: 10.3390/cells12030368.
6
Circulating tissue inhibitor of metalloproteinases 1 (TIMP-1) at COVID-19 onset predicts severity status.
Front Med (Lausanne). 2022 Nov 29;9:1034288. doi: 10.3389/fmed.2022.1034288. eCollection 2022.
9
α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.
Life (Basel). 2022 Mar 9;12(3):396. doi: 10.3390/life12030396.
10
Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
Front Pharmacol. 2022 Feb 1;13:805708. doi: 10.3389/fphar.2022.805708. eCollection 2022.

本文引用的文献

1
Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.
J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):70-5. doi: 10.1016/s0190-9622(00)90011-2.
2
Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts.
J Invest Dermatol. 1998 Apr;110(4):416-21. doi: 10.1046/j.1523-1747.1998.00138.x.
4
Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts.
J Invest Dermatol. 1997 Mar;108(3):281-4. doi: 10.1111/1523-1747.ep12286457.
6
Decreased collagenase expression in cultured systemic sclerosis fibroblasts.
J Invest Dermatol. 1994 Sep;103(3):359-63. doi: 10.1111/1523-1747.ep12394936.
10
Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.
J Am Acad Dermatol. 1995 Dec;33(6):973-8. doi: 10.1016/0190-9622(95)90289-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验